Content Library

When it comes to neuropathology studies, there is no one-size-fits-all approach.

Biotherapeutics like cell and gene therapies, nucleic acids, and proteins show promise for treating many neurodegenerative disorders.

Products such as cytotoxic chemotherapeutics and AAV-based gene therapies are associated with gangliotoxicity. Despite this, prior toxicology guidance provided no recommendations for which sensory and autonomic ganglia to evaluate in nonclinical general toxicity studies.